Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
NCT07632118Phase 3Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic cancer (PC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 24 months. Started May 2026; status: recruiting.
02
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07632118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632118.